I think the question is why Cecchi has assigned his invention to Anavex?
My read of this patent app included the notion that the ERP will provide a link to A2-73 outpatient treatment as a service/treatment/product and also as part of any ongoing patient support system. I am thinking this treatment w/A2-73 and periodic ERP monitoring (assuming positive Biomarker support systems) will eventually present an alternative outpatient treatment to being institutionalized(warehoused) as an AD/Dementia patient. This is all based on a common sense understanding of ERP capability/sensitivity to predicted levels of sensory/cognitive processing. My guess connecting dots w/o any medical training to speak of.
The patent is strange in several ways. I just don't see how it offers A273 any significant protection or lifespan. It is a little bipolar with flight of ideas -- first detailing composition, then intermittent use, then ERP. The only value I can see is that maybe they envision using the ERP to guide therapy (i.e if no response go up on dose and if good response move to intermittent use). Intermittent dosing is not used in any drug studies --- does trying to protect this aspect with a patent mean that they expect more side effects (I'll avoid t*******) on daily use than intermittent use? Are they planning on doing intermittent dosing on a future phase 3?
Market Data 
Markets 
